Targeting Rare, "Orphan", Diseases

Novel therapies for the treatment and prevention of neurodegenerative conditions

Learn More

About Intellect Neurosciences

We are a research-based, biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare, neurodegenerative, “orphan” diseases with high unmet medical need.

Learn More

Pipeline

Our current focus is to establish proof of concept for our anti-TauC3 antibody, a therapeutic monoclonal antibody targeting a truncated form of tau protein, licensed by Intellect from Northwestern University on an exclusive basis.

Learn More

Investor Relations

Intellect Neurosciences, Inc.

Symbol OTCQB: ILNS
Price
Change
Volume
Day Low/High
52 Week Low/High